2011 Volume 62 Issue 4 Pages 529-536
The clinical effects of tokishigyakukagoshuyushyokyoto for vascular intermittent claudication were investigated by treadmill test with 2.4 km/hour and 12 degree. Thirty three patients with Arteriosclerosis Obliterans (ASO) chose either administration of cilostazol (Group I) or tokishigyakukagoshuyushyokyoto (Group II). After limitation of improvement by cilostazol in Group I, tokishigyakukagoshuyushyokyoto was administered (Group III). The distance where patients were able to walk to the limit was assumed to be the maximum walking distance. Change rate of absolute claudication distance (ACD) was calculated as ratio of maximum walking distance after and before treatment.
The median of change rate of ACD in Group I one and three month after treatment were 130.5% and 145.5%, respectively. The median of change rate of ACD in Group II one and three month after treatment were 111.6% and 122.7%, respectively. Finally, the median of change rate of ACD in Group III one and three month after treatment were 112.0% and 112.3%, respectively.
Either cilostazol or tokishigyakukagoshuyushyokyoto was effective for vascular intermittent claudication. Moreover, tokishigyakukagoshuyushyokyoto showed additional effect after limitation of improvement by cilostazol.
